Integrated Multi-Omics Strategies for Identifying Novel Therapies in Psoriasis

Clicks: 2
ID: 315309
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #746 of 835 articles by views in BMC Bioinformatics

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 835 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Motivation Psoriasis is a chronic, immune-mediated disorder with an unmet need for effective treatments. To systematically prioritize therapeutic targets, we integrated proteome-wide Mendelian randomization (MR) with expression validation in blood/skin, genetic susceptibility analysis in the UK Biobank, differential gene expression (DGE) from bulk and single-cell RNA sequencing (scRNA-seq), colocalization, pathway enrichment, and protein-protein interaction analyses. Results Proteome-wide MR identified 29 candidate protein targets (Bonferroni-corrected), all replicated in independent datasets. Fifteen targets showed significant expression associations in blood or skin. Eleven proteins—UBLCP1, IL23A, ASF1A, RARRES2, ICAM1, PRSS53, ICAM5, GCA, IL2RA, DBI, and NFKB1—exhibited consistent directional effects with their genes. Genetic analysis confirmed 20 target-specific polygenic scores for psoriasis and five for psoriatic arthritis. DGE analysis identified 13 targets in bulk and 13 in scRNA-seq—primarily in keratinocytes and immune cells—with IL2RA, COMP, and A2ML1 dysregulated across both. Colocalization analysis implicated shared causal variants for psoriasis in ASF1A, CD8A, CTF1, IL7R, MMP12, RARRES2, XCL2, DBI, IL23A, IL2RA, SGSH, and TIMD4. Enrichment analyses highlighted involvement in cytotoxicity, immune regulation, and JAK-STAT signaling. Eighteen targets interacted with approved anti-psoriasis drugs. Notably, drugs targeting IL2RA, IL7R, CTF1, ICAM1, MMP12, NFKB1, CD8A, DDX58, IL12A, SGSH, and FAP are approved or in trials for other diseases, suggesting repurposing potential. Our integrative multi-omics approach prioritized 29 high-confidence targets, including 13 novel candidates (RARRES2, ASF1A, CTF1, DBI, B3GNT2, CD8A, TIMD4, CRTAM, SGSH, XCL2, DAPK2, A2ML1, and FAP). Several high-priority targets—such as IL2RA, IL23, MMP12, RARRES2, IL7R, and ICAM1—were supported across analytical layers. These findings provide a robust foundation for psoriasis drug development. Availability The code used for the analyses in this manuscript has been archived in Zenodo at [DOI: 10.5281/zenodo.19692128]. Supplementary information Supplementary data are available at Bioinformatics online.
Reference Key
openalex_W7162759401 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shucheng Si, Xiaoxiao Wang, Siyan Zhan
Journal BMC Bioinformatics
Year 2026
DOI
10.1093/bioinformatics/btag347
URL
https://doi.org/10.1093/bioinformatics/btag347
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.